Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Dec;136(6):1541-1547.e11.
doi: 10.1016/j.jaci.2015.04.045. Epub 2015 Jun 12.

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood

Zaraquiza Zolkipli  1 , Graham Roberts  2 , Victoria Cornelius  3 , Bernie Clayton  4 , Sarah Pearson  1 , Louise Michaelis  1 , Ratko Djukanovic  5 , Ramesh Kurukulaaratchy  6 , S Hasan Arshad  7
Affiliations
Free article
Randomized Controlled Trial

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood

Zaraquiza Zolkipli et al. J Allergy Clin Immunol. 2015 Dec.
Free article

Abstract

Background: Children born to atopic parents are at increased risk of sensitization to environmental allergens.

Objective: We sought to demonstrate proof of concept for oral immunotherapy to high-dose house dust mite (HDM) allergen in infancy in the prevention of allergen sensitization and allergic diseases.

Methods: This was a prospective, randomized, double-blind, placebo-controlled, proof-of-concept study involving 111 infants less than 1 year of age at high risk of atopy (≥ 2 first-degree relatives with allergic disease) but with negative skin prick test responses to common allergens at randomization. HDM extract (active) and appropriate placebo solution were administered orally twice daily for 12 months, and children were assessed every 3 months. Coprimary outcomes were cumulative sensitization to HDM and sensitization to any common allergen during treatment, whereas development of eczema, wheeze, and food allergy were secondary outcomes. All adverse events were recorded.

Results: There was a significant (P = .03) reduction in sensitization to any common allergen (16.0%; 95% CI, 1.7% to 30.4%) in the active (5 [9.4%]) compared with placebo (13 [25.5%]) treatment groups. There was no treatment effect on the coprimary outcome of HDM sensitization and the secondary outcomes of eczema, wheeze, and food allergy. The intervention was well tolerated, with no differences between active and placebo treatments in numbers or nature of adverse events.

Conclusion: Prophylactic HDM oral immunotherapy is well tolerated in children at high heredity risk. The results met the trial's prespecified criteria for proof of concept in reducing sensitization to any allergen; however, no significant preventive effect was observed on HDM sensitization or allergy-related symptoms.

Keywords: Atopy; allergen; early childhood; house dust mite; infant; oral immunotherapy; primary prevention; randomized controlled trial.

PubMed Disclaimer

Publication types